JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Cellectis SA (CLLS – Research Report) today and set a price target of $11.00. The company’s shares closed yesterday at $2.34.
According to TipRanks, Tuerkcan is a 3-star analyst with an average return of 2.0% and a 30.22% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Mirati Therapeutics, Vor Biopharma, and Cellectis SA.
Cellectis SA has an analyst consensus of Moderate Buy, with a price target consensus of $10.50, representing a 348.72% upside. In a report released on November 30, Robert W. Baird also maintained a Buy rating on the stock with a $10.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $9.30 and a one-year low of $2.00. Currently, Cellectis SA has an average volume of 84.55K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Read More on CLLS:
- Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
- Oppenheimer emerging biotech analysts to hold analyst/industry conference call
- Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
- Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
- Monthly information on share capital and company voting rights
